Evidence map›Paper›PMID 28523571›Full record

ArticleInternational journal of hematology2017

Congenital immature pure erythroid leukemia with E-cadherin expression.

Akihiro Tamura, Suguru Uemura, Atsuro Saito, Saki Okubo, Nanako Nino, Teppei Tahara, Takehito Yokoi, Kenji Kishimoto, Toshiaki Ishida, Daiichiro Hasegawa and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. TheFrontiers in oncology · 2026
    Article
  3. Haematologica · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Akihiro TamuraDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan. tamura_kch@hp.pref.hyogo.jp.
Suguru UemuraDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Atsuro SaitoDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Saki OkuboDepartment of Neonatology, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Nanako NinoDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Teppei TaharaDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Takehito YokoiDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Kenji KishimotoDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Toshiaki IshidaDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Keiichiro KawasakiDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Seiji YoshimotoDepartment of Neonatology, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Hideto NakaoDepartment of Neonatology, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Makiko YoshidaDepartment of Diagnostic Pathology, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Children's Cancer Center, Hyogo Prefectural Kobe Children's Hospital, Minatojima-Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Kobe Children's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital pure erythroid leukemia is exceedingly rare and poses a diagnostic challenge. We report an atypical case of congenital pure erythroid leukemia that did not express typical erythroid markers. The patient presented with a high white blood cell count with blastic cells at birth. Although flow cytometric analyses of peripheral blood and bone marrow showed a large CD45-negative cell population, we did not identify any evidence of monoclonality. While the circulating blasts decreased with only supportive care, hepatomegaly with multiple nodules was accompanied by liver failure, disseminated intravascular coagulation, and development of hemophagocytic lymphohistiocytosis. Pathological examination of the liver biopsy specimen revealed a small round cell tumor that was negative for nearly all hematopoietic cell markers, including classical erythroid cell markers, and positive for CD43, CD71, and E-cadherin, an early erythroid marker epithelial calcium-dependent adhesion protein, suggesting that these tumor cells originated from an immature erythroblast. We found high β-catenin and c-Myc protein expression, which were not previously described in pure erythroid leukemia. Cytosine arabinoside temporarily alleviated clinical symptoms; however, the patient died of progressive disease at 8 months of age. This case indicates that E-cadherin is useful for diagnosing pure erythroid leukemia, even in immature cases.

Indexed as

Blast CrisisLeukemia, Erythroblastic, AcuteAntigens, DifferentiationBiomarkers, TumorFatal OutcomeFemaleHumansInfant, NewbornNeoplasm ProteinsAntigens, DifferentiationBiomarkers, TumorNeoplasm ProteinsCongenital leukemiaCongenital pure erythroid leukemiaE-cadherinPure erythroid leukemia

Identifiers

PMID28523571
OpenAlexW2614118562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.